Sjögren syndrome

Global CD19 Antibody Market and Clinical Pipeline Outlook 2023-2028: A $10 Billion+ Market by 2028 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 22, 2023

The "Global CD19 Antibody Market and Clinical Pipeline Outlook 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global CD19 Antibody Market and Clinical Pipeline Outlook 2028" report has been added to ResearchAndMarkets.com's offering.
  • This can be attributed to the rapid regulatory approvals, and the current pipeline of investigational CD19-targeting therapies shows potential for a further surge of this market cap.
  • CD19-targeting therapies have made a significant impact on the clinical landscape of cancer treatment.
  • Global CD19 Antibody Market and Clinical Pipeline Outlook 2028 Report Highlights:
    Global CD19 Antibody Market Opportunity: > USD 10 Billion By 2028
    Commercially Approved CD 19 Antibodies: 10 Antibodies
    Comprehensive Insights On CD19 Antibodies In Clinical Trials: > 190 Antibodies
    Global CD19 Antibodies Clinical Trials By Company, Indication and Phase

BLUE CROSS BLUE SHIELD OF MASSACHUSETTS ANNOUNCES ENHANCED DENTAL BENEFITS FOR MEMBERS WITH MENTAL HEALTH CONDITIONS

Retrieved on: 
Wednesday, December 13, 2023

BOSTON, Dec. 13, 2023 /PRNewswire/ -- Blue Cross Blue Shield of Massachusetts (Blue Cross) today announced a market-leading expansion of its Dental Blue benefits to ensure members of all ages with mental health conditions have access to enhanced services to support their oral health.

Key Points: 
  • BOSTON, Dec. 13, 2023 /PRNewswire/ -- Blue Cross Blue Shield of Massachusetts (Blue Cross) today announced a market-leading expansion of its Dental Blue benefits to ensure members of all ages with mental health conditions have access to enhanced services to support their oral health.
  • Blue Cross currently offers expanded dental benefits to members with diabetes, heart disease, stroke, oral cancer, Sjogren's Syndrome and women who are pregnant.
  • These conditions can put patients at higher risk for developing oral health conditions, and these benefits can help members manage oral health complications related to their medical condition.
  • Blue Cross' dental plan reached a new milestone of more than 1 million members in early 2023.

THE AUTOIMMUNE ASSOCIATION ANNOUNCES ITS ANNUAL COMMUNITY SUMMIT FOR PATIENTS AND CARE PROVIDERS

Retrieved on: 
Tuesday, October 3, 2023

CLINTON TOWNSHIP, Mich., Oct. 3, 2023 /PRNewswire/ -- The Autoimmune Association, the world's leading nonprofit organization dedicated to autoimmune awareness, advocacy, education, and research, announces its third annual Autoimmune Community Summit on Thursday, October 5 and Friday, October 6, 2023.

Key Points: 
  • This annual free, virtual event is open to anyone affected by autoimmune disease to share information, be inspired, create new connections and learn about the latest treatments.
  • While the exact cause of autoimmune diseases is not fully understood, they are thought to result from a combination of genetic and environmental factors.
  • This two-day event, designed for patients and care partners, offers educational and empowering sessions led by autoimmune experts including scientists and researchers, physicians, mental health experts, policy leaders and patient advocates.
  • The Autoimmune Community Summit will take place from 11:30 a.m. to 3:00 p.m. EDT on Thursday, October 5 and Friday October 6.

Trinity Biotech Announces Q2 2023 Financial Results

Retrieved on: 
Tuesday, October 3, 2023

DUBLIN, Ireland, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced the Company’s results for the quarter ended June 30, 2023.

Key Points: 
  • DUBLIN, Ireland, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced the Company’s results for the quarter ended June 30, 2023.
  • Total revenue for fiscal Q2, 2023 was $13.9m (excluding Fitzgerald Industries, which was disposed of in April 2023).
  • In August, Trinity Biotech received U.S. FDA 510(k) clearance for the Premier Resolution System, the automated analyzer for accurate & precise quantification of haemoglobin variants.
  • Total revenues for Q2, 2023 were $13.9m which compares to $15.4m in Q2, 2022, a decrease of 9.8% and which were broken down as follows:

Sjogren's Syndrome Drug Pipeline Research Report 2023: Comprehensive Exploration of 20+ Companies and 25+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Monday, September 4, 2023

The "Sjogren's syndrome - Pipeline Insight, 2023" report offers a comprehensive exploration of the landscape, encompassing over 20 companies and more than 25 pipeline drugs within the realm of Sjogren's syndrome.

Key Points: 
  • The "Sjogren's syndrome - Pipeline Insight, 2023" report offers a comprehensive exploration of the landscape, encompassing over 20 companies and more than 25 pipeline drugs within the realm of Sjogren's syndrome.
  • The report not only sheds light on active pipeline products but also presents insights into inactive pipeline products within this domain.
  • Within this comprehensive report lies a detailed portrayal of the current landscape and the potential growth prospects within this therapeutic indication.
  • With an overview of Sjogren's syndrome treatment guidelines and disease overview, the report constructs a thorough picture of the Sjogren's syndrome pipeline landscape.

Prevent Blindness Declares July as Dry Eye Awareness Month to Educate Public on Eye Disease that Affects more than 16 Million Americans

Retrieved on: 
Thursday, July 20, 2023

CHICAGO, July 20, 2023 /PRNewswire-PRWeb/ -- Nearly 16 million Americans have dry eye, according to the National Eye Institute (NEI). Dry eye occurs when there is not enough tear film produced, the tear film is not draining properly from the eye, or the tear film is not the quality needed to maintain the health of the eye. If left untreated, dry eye can cause damage to the cornea.

Key Points: 
  • In an effort to educate the public on dry eye, Prevent Blindness , the nation's leading nonprofit eye health organization, has declared July as "Dry Eye Awareness Month."
  • Patients must inform their eyecare professional of all medications they are taking in order to treat dry eye and other eye conditions effectively.
  • "Dry eye is a serious condition that may have long-term effects on eye health, if left untreated," said Jeff Todd, president and CEO of Prevent Blindness.
  • For more information on dry eye, please visit the Prevent Blindness resource page at PreventBlindness.org/understanding-dry-eye .

Romeg Therapeutics Announces Issuance of U.S. Patent for Pilocarpine Oral Solution

Retrieved on: 
Wednesday, February 1, 2023

11,564,909 (the '909 patent) directed to the methods and composition of ROMEG's proprietary formulation of pilocarpine.

Key Points: 
  • 11,564,909 (the '909 patent) directed to the methods and composition of ROMEG's proprietary formulation of pilocarpine.
  • The '909 patent reflects a significant addition to Romeg's current intellectual property portfolio and covers the composition claims of pilocarpine oral solution and its therapeutic indications.
  • "We are pleased with the USPTO's issuance of the '909 patent today," said Naomi Vishnupad, Ph.D., Chief Scientific Officer and Partner of Romeg.
  • Romeg is committed to addressing the need of these patients with a palatable, easy to administer pilocarpine oral solution therapy.

SinoMab Awarded the "Most Valuable Pharmaceutical and Medical Company" in the Selection of the "7th Hong Kong Golden Stocks Awards"

Retrieved on: 
Monday, December 19, 2022

SinoMab was awarded the "Most Valuable Pharmaceutical and Medical Company", highlighting the attention and recognition of the industry and investors on the Company's value and innovation capabilities, which is a great encouragement and even a spur to SinoMab.

Key Points: 
  • SinoMab was awarded the "Most Valuable Pharmaceutical and Medical Company", highlighting the attention and recognition of the industry and investors on the Company's value and innovation capabilities, which is a great encouragement and even a spur to SinoMab.
  • SinoMab is the first Hong Kong-based listed biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics, primarily monoclonal antibody ("mAb")-based biologics, for the treatment of immunological diseases.
  • Currently, various candidate products for all-field indications of autoimmune diseases in SinoMab's layout have started clinical trials successively and are progressing steadily.
  • Previously, SinoMab appointed Mr. Shanchun WANG as the President (China) of the Company, mainly responsible for the China operation.

Global Dry Eye Treatment Devices Market Report 2022: An Upsurge in The Number of Eye Care Facilities Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, November 14, 2022

The "Global Dry Eye Treatment Devices Market Size, Share & Industry Trends Analysis Report by Technology, End-user, Regional Outlook and Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Dry Eye Treatment Devices Market Size, Share & Industry Trends Analysis Report by Technology, End-user, Regional Outlook and Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering.
  • The Global Dry Eye Treatment Devices Market size is expected to reach $348.8 million by 2028, rising at a market growth of 7.4% CAGR during the forecast period.
  • Several medical remedies and methods are either on the market or being researched for the management of DED.
  • The number of people with dry eyes has grown recently for a variety of causes, leading to an increase in eye care facilities.

RemeGen Biosciences to Present New Data Updates in ACR 2022

Retrieved on: 
Friday, November 11, 2022

This event will present Telitacicept phase III clinical trial data on Systematic lupus erythematosus (SLE) and data from the phase II clinical trial for Sjorgren's syndrome.

Key Points: 
  • This event will present Telitacicept phase III clinical trial data on Systematic lupus erythematosus (SLE) and data from the phase II clinical trial for Sjorgren's syndrome.
  • Telitacicept for Systematic Lupus Erythematosus, data from phase III trial
    This is a 52-week, randomized, double-blind, placebo-controlled, phase III clinical trial (NCT04082416).
  • RemeGen, Ltd. ("RemeGen") is a leading biopharmaceutical company in China dedicated to fulfilling unmet medical needs for patients with life-threatening conditions.
  • Since its inception in 2008, RemeGen has created more than 10 novel drug molecules in various clinical development stages.